NMRA - Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder.
As of Jun 30, 2026: spot at $1.69, ATM IV 101.1%, max pain $2.00, net GEX -$11.1K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $303.9M
- Beta
- 2.76
- 52-Week Range
- 0.716-3.65
- CEO
- Daljit Singh Aurora
- Employees
- 110
- IPO Date
- Sep 15, 2023
- Exchange
- NASDAQ
What NMRA Looks Like to Options Traders Today
IV rank of 19.9% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); negative net gamma exposure (-$11.1K) means dealers hedge with trend, amplifying realized volatility and accelerating directional moves; the 25-delta skew (-0.323) prices puts richer than calls, the typical equity downside-protection skew.
What This Page Covers
The NMRA overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked NMRA overview questions
- What is NMRA?
- NMRA is the ticker symbol for Neumora Therapeutics, Inc. Common Stock, a listed security. Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Listed on NASDAQ. NMRA is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the NMRA options snapshot look like today?
- As of Jun 30, 2026, the NMRA options snapshot shows spot at $1.69, ATM IV 101.1%, IV rank 19.9%, max pain $2.00, net GEX -$11.1K, expected move 28.98%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are NMRA's key statistics?
- Neumora Therapeutics, Inc. Common Stock (NMRA) carries a market capitalization of $303.9M, beta of 2.76 relative to the broader market, 52-week range of 0.716-3.65. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does NMRA belong to?
- Neumora Therapeutics, Inc. Common Stock operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare NMRA's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the NMRA data on this page?
- The options snapshot above is dated Jun 30, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).